Cell Source Inc
OTCQB:CLCS

  • LAST PRICE
    0.5400
  • TODAY'S CHANGE (%)
    0.1145 (26.9095%)
  • Bid / Lots
    0.4210/ 30
  • Ask / Lots
    0.5800/ 50
  • Open / Previous Close
    0.5400 / 0.4255
  • Day Range
    0.5400
    0.5400
  • 52 Week Range
    0.0002
    0.7500
  • Volume
    100

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 21, 2024

      Show headlines and story abstract

    • 2:00PM ET on Thursday Nov 21, 2024 by Accesswire
      Companies Mentioned: CLCS

      First-of-Its-Kind Success in Mismatched Donor Stem Cell Transplantation: Engraftment Under Mild Immune Suppression with Minimal Graft-versus-Host Disease

      NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source", or the "Company"), a pioneer in Veto Cell-based immunotherapy, today shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes.

    • 8:02AM ET on Thursday Nov 21, 2024 by Dow Jones
      Companies Mentioned: CLCS

      First-of-Its-Kind Success in Mismatched Donor Stem Cell Transplantation: Engraftment Under Mild Immune Suppression with Minimal Graft-versus-Host Disease

      NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source", or the "Company"), a pioneer in Veto Cell-based immunotherapy, today shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes.

Peers Headlines